(Sharecast News) - 4basebio said on Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial using an mRNA therapy developed with the company's proprietary 'opDNA' synthetic DNA template, marking what it called a major milestone for the technology's adoption in...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE